Safety and effectiveness of the sodium-glucose cotransporter inhibitor bexagliflozin in cats newly diagnosed with diabetes mellitus

202334 citationsJournal Articlegold Open Access

Authors

Michael J. Hadd · Department of Conservation and Recreation

Stephen E. Bienhoff · Argentine Antarctic Institute

Susan E. Little · Bytown Cat Hospital

Samuel Geller · SignPath Pharma (United States)

Jennifer Ogne‐Stevenson · Argentine Antarctic Institute

Thomas J. Dupree · Department of Conservation and Recreation

J. Catharine Scott‐Moncrieff

Abstract

Bexagliflozin decreased hyperglycemia and observed clinical signs in cats newly diagnosed with DM. As a once-daily PO medication, bexagliflozin may simplify management of DM in cats.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Veterinary Internal Medicine

Volume 37, Issue 3, pp. 915-924

DOI: 10.1111/jvim.16730

Field-Weighted Citation Impact: 6.88